42results about How to "Suitable for routine determination" patented technology

The invention discloses a method for determining the concentration of tadalafil in blood plasma by liquid chromatography-mass spectrometry, which adopts a liquid chromatography-mass spectrometry system for determination and comprises the following steps: taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction and pretreatment, performing separating by usinga chromatographic column, and performing detecting by using a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for measuring the blood concentration of tadalafil; according to the method, the linear range of a plasma standard curve is 1-600ng/mL, the intra-batch precision RSD and theinter-batch precision RSD are both less than +/-15%, and the method is suitable for measuring the concentration of tadalafil in plasma.

The invention discloses a method for determining concentration of carbamazepine in plasma by liquid chromatography mass spectrometry. A liquid chromatography mass spectrometry system is used for determining. A sample to be determined is added with a certain amount of mixed organic solvent to extract twice, is separated through a chromatographic column after pretreatment, and is detected by a massspectrometer. The method is rapid, accurate, high in sensitivity, and simple and convenient to operate. The method provides a basis for the blood drug concentration determination of carbamazepine. Thelinear range of a plasma standard curve in the method is 5 to 1000 ng/mL. The intra-batch and inter-batch precision RSD are less than +/-15%. The method is suitable for determining the concentrationof carbamazepine in the plasma.

The invention discloses a met/hod for determining the concentration of 5'-methoxyl-3',4'-methylenedioxyphenyl cinnamic acid isobutyl amide in plasma. A liquid chromatography-mass system is adopted to determine. The method comprises the following steps: taking a to-be-determined sample first, adding a certain quantity of organic solvent for extraction, separating through a chromatographic column after pretreatment, and determining by using a mass spectrometry detector. The method disclosed by the invention has the advantages of rapidity, accuracy, high sensitivity, simplicity and convenience in operation and is suitable for determining the concentration of 5'-methoxyl-3',4'-methylenedioxyphenyl cinnamic acid isobutyl amide in plasma.

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to an analysis method for determining dimethyl sulfate in pyraclostrobin by a gas chromatography-mass spectrometry method. The invention discloses an analysis method for measuring dimethyl sulfate in pyraclostrobin by gas chromatography-mass spectrometry. The analysis method comprises the following steps: (1) preparing a standard solution; (2) drawing a standard curve; and (3) determining the content of dimethyl sulfate in the sample. Compared with the prior art, the method disclosed by the invention has the advantages of simplicity and convenience in sample preparation, small sample dosage and suitability for conventional determination; the sensitivity is high, and the lowest detection limit of dimethyl sulfate is 0.20 mg/kg. The method is simple in test process, high in sensitivity and good in accuracy.

The invention discloses a method for determining the concentration of omeprazole in plasma by liquid chromatography-mass spectrometry. The method adopts a liquid chromatography-mass spectrometry system for determination and comprises the steps of firstly taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction and pretreatment, separating by a chromatographic column, and detecting by a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for measuring the blood concentration of omeprazole; the linear range of a plasma standard curve of the method is 2 to 1500ng/mL, the intra-batch and inter-batch precision RSD is less than +/-15%, and the method is suitable for determining the concentration of omeprazole in plasma.

The invention provides a method for determining the concentration of hydrochlorothiazide, losartan and active hydroxy acid metabolite 5-carboxylic acid losartan in plasma by liquid chromatography-massspectrometry. The method comprises the following steps of: (1) pretreating a plasma sample; (2) detecting by liquid chromatography-mass spectrometry; (3) preparing a standard curve; and (4) determining the concentration of hydrochlorothiazide, losartan and active hydroxy acid metabolite 5-carboxylic acid losartan in plasma. The method provided by the invention is rapid, accurate, high in sensitivity and simple to operate, and serves clinical application of medicines.

The invention discloses a method for determining the concentration of lacosamide in blood plasma by liquid chromatography-mass spectrometry, which adopts a liquid chromatography-mass spectrometry system for determination, and comprises the following steps: taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction and pretreatment, separating by a chromatographic column, and detecting by a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for determining the blood concentration of lacosamide; and according to the method, the linear range of the plasma standard curve is 100-15000 ng/mL, the intra-batch precision RSD and the inter-batch precision RSD are both smaller than +/-15%, and the method is suitable for measuring the concentration of lacosamide in plasma.

The invention discloses a method for determining the concentration of cetirizine in blood plasma by liquid chromatography-mass spectrometry, which adopts a liquid chromatography-mass spectrometry system for determination, and comprises the following steps: taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction and pretreatment, performing separating by using a chromatographic column, and performing detecting by using a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for measuring the blood concentration of cetirizine; according to the method, the linear range of the plasma standard curve is 1-600ng/mL, the intra-batch precision RSD and the inter-batch precision RSD are both less than +/-15%, and the method is suitable for measuring the concentration of cetirizine in plasma.

The invention discloses a method for determining the concentration of serodosin and KMD-3213G in plasma by using liquid chromatography-mass spectrometry. The concentration of serodosin and KMD-3213G in the plasma is determined by using a liquid chromatography-mass spectrometry system; taking a sample to be tested first, and adding a certain amount of mixed organic solvent for extraction twice; after pretreatment, performing chromatographic column separation, and then detecting by using a mass spectrometry detector. The method for determining the concentration of serodosin and KMD-3213G in theplasma by using the liquid chromatography-mass spectrometry disclosed by the invention has the advantages of rapid, accurate, high sensitivity and simple operation, and provides a basis for determining the blood concentration of serodosin and KMD-3213G. According to the plasma standard curve of the method, the quantitative range of serodosin is 0.2-60 ng/mL, the quantitative range of KMD-3213G is0.2-40 ng/mL, and the intra-assay and inter-assay precisions RSDs are less than +/-15%, which is suitable for determining the concentration of serodosin and KMD-3213G in the plasma.

The invention discloses a method for determining the concentration of azithromycin in plasma by liquid chromatography-mass spectrometry, which adopts a liquid chromatography-mass spectrometry system for determination and comprises the steps of taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction, separating by a chromatographic column after pretreatment,and detecting by a mass spectrum detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for measuring the plasma concentration of azithromycin. According to the method, the linear range of a plasma standard curve is 1-500ng/mL, the intra-batch precision RSD and the inter-batch precision RSD are both less than +/-15%, and the method is suitable for determining the concentration of azithromycin in plasma.

The invention discloses a method for detecting the concentration of hydrocortisone in plasma by liquid chromatography-mass spectrometry. The method adopts a liquid chromatography-mass spectrometry system for determination and comprises the following steps: firstly taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction, pretreating, separating by a chromatographic column, and detecting by a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for determining the blood concentration of the hydrocortisone; and the linear range of the plasma standard curve of the method is 0.01-3 ng/mL, the intra-batch and inter-batch precision RSD is less than +/-15%, and the method is suitable for measuring the concentration of the hydrocortisone in the plasma.

The invention discloses a method for determining concentration of dexamethason in plasma by liquid chromatography mass spectrometry. A liquid chromatography mass spectrometry system is used for determining. A sample to be determined is added with a certain amount of mixed organic solvent to extract twice, is separated by a chromatographic column after pretreatment, and is detected by a mass spectrometer. The method is rapid, accurate, high in sensitivity, and simple and convenient to operate. The method provides a basis for the blood drug concentration determination of dexamethason. The linearrange of a plasma standard curve in the method is 0.1 to 20 ng/mL. The intra-batch and inter-batch precision RSD are less than +/-15%. The method is suitable for determining the concentration of dexamethason in the plasma.

The invention provides a method for determining concentrations of prednisone, prednisone acetate and active metabolite prednisolone thereof in blood plasma by means of liquid chromatography-mass spectrometry. The method comprises the steps of: (1) pretreating a blood plasma sample; (2) detecting the blood plasma sample by adopting liquid chromatography-mass spectrometry; (3) preparing a standard curve; and (4) determining the concentrations of prednisone, prednisone acetate and active metabolite prednisolone thereof in the blood plasma. The pretreatment method disclosed by the invention is simple, high in specificity and high in sensitivity, and the method is rapid, precise, high in sensitivity, simple in operation and suitable for clinical application of medicines.

The invention discloses a method for determining the concentration of prucalopride in blood plasma by liquid chromatography-mass spectrometry, which adopts a liquid chromatography-mass spectrometry system for determination, and comprises the following steps: taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction and pretreatment, separating by a chromatographic column, and detecting by a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for measuring the blood concentration of prucalopride; and according to the method, the linear range of the plasma standard curve is 0.1-10ng/mL, the intra-batch precision RSD and the inter-batch precision RSD are both smaller than +/-15%, and the method is suitable for measuring the concentration of prucalopride in plasma.

The invention discloses a method for determining concentration of licorice glycoside C2 in blood plasma. A liquid chromatography-mass spectrometry system is adopted for determination, firstly, a to-be-determined sample is taken, a certain quantity of organic solvent protein precipitation solutions are added, a chromatographic column is used for separation after pretreatment, and a mass spectrometry detector is used for detection. The method is rapid, accurate, high in sensitivity, simple and convenient to operate and suitable for determining the concentration of licorice glycoside C2 in the blood plasma.

The invention discloses a method for measuring the concentration of felodipine in plasma by liquid chromatography-mass spectrometry. The method adopts a liquid chromatography-mass spectrometry system for measurement, and comprises the following steps: firstly taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction and pretreatment, separating by a chromatographic column, and detecting by a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for measuring the blood concentration of felodipine; and the linear range of the plasma standard curve of the method is 0.02-4 ng/mL, the intra-batch and inter-batch precision RSD is less than +/-15%, and the method is suitable for measuring the concentration of felodipine in the plasma.